WaveMan
WaveMan · Company
NAUT · Nautilus Biotechnology, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

NAUT Nautilus Biotechnology (NAUT) Insider Trading, Ownership & Congress Trades

Medical Devices · Laboratory analytical instruments · CIK 0001808805
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
60
13F, latest reported quarter

What the filings say about NAUT

Insiders, 180 days
-$11.8M net sold
1 seller · 0% of sales under a 10b5-1 plan

Nautilus Biotechnology insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Nautilus Biotechnology, Inc. insiders sold a net $11.8M of stock across 46 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
AH Bio Fund II, L.P.
SELL
2026-06-04 SECtraded 2026-06-02
4,615,974
$10.8M
+2.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 39.5% of the 11,682,032 shares held after it.
  • No other insider sold within 30 days.
  • 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider AH Bio Fund II, L.P. sold about $10.8M of NAUT on Jun 2, 2026, the largest insider sale at the company on our record; 60 funds added in the latest 13F quarter.
AH Bio Fund II, L.P.
SELL
2026-06-04 SECtraded 2026-06-02
384,026
$902.5K
+2.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 39.5% of the 971,885 shares held after it.
  • No other insider sold within 30 days.
  • 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider AH Bio Fund II, L.P. sold about $902.5K of NAUT on Jun 2, 2026, the largest insider sale at the company on our record; 60 funds added in the latest 13F quarter.
Patel Sujal M
CEO, President, and Secretary
BUY
2026-03-04 SEC
25,000
$65.2K
+0.0%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 buys), the last on Sep 8, 2025.
  • -12.1% median (+15.7% mean) 90-day return after 15 previous buys.
  • The trade is 0.2% of the 10,366,721 shares held after it.
  • No other insider bought within 30 days.
  • 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO, President, and Secretary Patel Sujal M bought about $65.2K of NAUT on Mar 4, 2026; 60 funds added in the latest 13F quarter.
Suzuki Kentaro
Chief Marketing Officer
BUY
2025-11-10 SECtraded 2025-11-06
4,000
$6.0K
+47.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 4,000 shares held after it.
  • No other insider bought within 30 days.
  • 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Marketing Officer Suzuki Kentaro bought about $6.0K of NAUT on Nov 6, 2025; 60 funds added in the latest 13F quarter.
Patel Sujal M
CEO, President, and Secretary
BUY
2025-09-09 SECtraded 2025-09-08
83,500
$56.8K
+245.1%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 buys), the last on Sep 5, 2025.
  • -12.2% median (+3.3% mean) 90-day return after 14 previous buys.
  • The trade is 0.8% of the 10,341,721 shares held after it.
  • 1 other insider bought within 30 days.
  • 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO, President, and Secretary Patel Sujal M bought about $56.8K of NAUT on Sep 8, 2025; 1 other insider bought within 30 days and 60 funds added in the latest 13F quarter.
46 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 41 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$11.8M over 180 days
-$11.8M of it by a 10%+ holder
below 87% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
60 funds bought in last quarter
below 52% of Medical Devices
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
8.3% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
more than 63% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch NAUT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+68.3%12M
-41%+30%+101%+172%2025-102025-122026-022026-042026-062026-082026-10 2026-06-02 · AH Bio Fund II, L.P. sold $10.8M2026-06-02 · AH Bio Fund II, L.P. sold $902.5K2026-03-04 · Patel Sujal M bought $65.2K2025-11-06 · Suzuki Kentaro bought $6.0K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NAUT: institutional holders (13F)

13F holdings, latest reported quarter
Cercano Management LLC
14,345,970 sh
$26.8M
PERCEPTIVE ADVISORS LLC
11,634,211 sh
$21.8M
a16z Capital Management, L.L.C.
9,063,054 sh
$16.9M
BlackRock, Inc.
2,687,226 sh
$5.0M
VANGUARD CAPITAL MANAGEMENT LLC
2,549,979 sh
$4.8M

Congress trades in NAUT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NAUT planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

NAUT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$243.1K position · as of 2026-06-30
0.2%
Ultra-Small Company Fund
$93.5K position · as of 2026-06-30
0.1%
JPMorgan Small Cap Value Portfolio
$156.7K position · as of 2026-06-30
0.0%
JPMorgan Small Cap Value Fund
$622.5K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$311.4K position · as of 2026-06-30
0.0%
U.S. Small Cap Equity Fund
$98.1K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $11.8M sold by insiders over 180 days, 60 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

NAUT financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$51.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-36.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-30.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-16.7%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Net income-$59.0M-$70.8M-$63.7M-$57.9M
EPS (diluted)-0.47-0.56-0.51-0.46
Operating cash flow-$50.7M-$59.1M-$51.7M-$45.8M
Cash$12.4M$27.6M$19.4M$114.5M
SEC XBRL, fiscal years, as known on 2026-10-28

NAUT Stock Sonar score 4/7 axes

Find similar shapesCompare

NAUT ranks highest on institutional and government (48th percentile) and risk and compliance (48th), and lowest on insider conviction (5th), among Medical Devices peers.

Profitability
42
Inputs
  • Return on equity-36.2% · 43 pct, sector of 183
  • Return on assets-30.0% · 40 pct, sector of 214
  • Return on invested capitalfewer than four consecutive quarters of operating income
  • Return on capital employedfewer than four consecutive quarters of operating income
Insider conviction
5
Inputs
  • Net Form 4 buying (codes P and S), 180d-$11.8M · 9 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
48
Inputs
  • Funds adding, latest quarter60 · 48 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
48
Inputs
  • Short interest, % of float+8.3% · 27 pct, sector of 241
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+7.6% · 68 pct, sector of 198
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NAUT filings, in plain words

Are Nautilus Biotechnology insiders buying or selling NAUT?

In the 180 days to 2026-10-28, Nautilus Biotechnology insiders were net sellers, a net $11.8M across purchases and sales reported on Form 4, by 1 seller.

Read the full summary

In the 180 days to 2026-10-28, Nautilus Biotechnology insiders were net sellers of NAUT, a net $11.8M across purchases and sales reported on Form 4 by 1 seller. Most of that figure, $11.8M, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies